Literature DB >> 8562464

New concepts regarding events that lead to end-stage heart disease.

J N Cohn1.   

Abstract

Cardiac dysfunction is a progressive process that eventuates in end-stage heart failure. This progression involves dilatation and hypertrophy of the left ventricle, characterized as left ventricular remodeling. This remodeling results in a falling left ventricular ejection fraction, worsening heart failure, and increased risk of lethal ventricular arrhythmias. Increased aortic impedance due to vasoconstriction, neurohormonal stimulation, and bioenergetic abnormalities all may contribute to the remodeling process. Therapeutic efforts aimed at halting this progressive process, especially if initiated early in the course of the disease, are most likely to exert a favorable effect.

Entities:  

Mesh:

Year:  1995        PMID: 8562464     DOI: 10.1007/bf00877859

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  29 in total

1.  Stretching cardiac myocytes stimulates protooncogene expression.

Authors:  I Komuro; T Kaida; Y Shibazaki; M Kurabayashi; Y Katoh; E Hoh; F Takaku; Y Yazaki
Journal:  J Biol Chem       Date:  1990-03-05       Impact factor: 5.157

2.  Elevated circulating levels of tumor necrosis factor in severe chronic heart failure.

Authors:  B Levine; J Kalman; L Mayer; H M Fillit; M Packer
Journal:  N Engl J Med       Date:  1990-07-26       Impact factor: 91.245

Review 3.  Cardioreparation and the concept of modulating cardiovascular structure and function.

Authors:  K T Weber; C G Brilla; J G Cleland; J N Cohn; L Hansson; A M Heagerty; J H Laragh; S Laurent; J P Ollivier; P Pauletto
Journal:  Blood Press       Date:  1993-03       Impact factor: 2.835

4.  Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction.

Authors: 
Journal:  N Engl J Med       Date:  1989-08-10       Impact factor: 91.245

5.  Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction.

Authors:  H D White; R M Norris; M A Brown; P W Brandt; R M Whitlock; C J Wild
Journal:  Circulation       Date:  1987-07       Impact factor: 29.690

6.  Norepinephrine-stimulated hypertrophy of cultured rat myocardial cells is an alpha 1 adrenergic response.

Authors:  P Simpson
Journal:  J Clin Invest       Date:  1983-08       Impact factor: 14.808

7.  Hemodynamic, left ventricular structural and hormonal changes after discrete myocardial damage in the dog.

Authors:  K M McDonald; G S Francis; P F Carlyle; K Hauer; J Matthews; D W Hunter; J N Cohn
Journal:  J Am Coll Cardiol       Date:  1992-02       Impact factor: 24.094

8.  Randomised trial of low-dose amiodarone in severe congestive heart failure. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA)

Authors:  H C Doval; D R Nul; H O Grancelli; S V Perrone; G R Bortman; R Curiel
Journal:  Lancet       Date:  1994-08-20       Impact factor: 79.321

Review 9.  Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system.

Authors:  K T Weber; C G Brilla
Journal:  Circulation       Date:  1991-06       Impact factor: 29.690

10.  Mechanism of death in heart failure. The Vasodilator-Heart Failure Trials. The V-HeFT VA Cooperative Studies Group.

Authors:  S Goldman; G Johnson; J N Cohn; G Cintron; R Smith; G Francis
Journal:  Circulation       Date:  1993-06       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.